PRINCETON, N.J., Nov 1 (Bernama-GLOBE NEWSWIRE) — SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced it has received its eighth ANDA approval from the US Food and Drug Administration (FDA).
The eighth approved ANDA is for Lidocaine Ointment USP, 5%, Package size: 1 ½ oz tube (35.44 g). This drug product is used for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. This drug has annual sales of about 60 million US dollars.